Want to see AU:1AD full AI Analyst Report?
Top Page
AdAlta Ltd.
(Sydney:1AD)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Upgraded
Date:08/22/26
The score is driven primarily by weak financial performance: revenue fell to zero in FY2026, losses persist, and cash burn remains significant, indicating continued reliance on external funding. Lower leverage (debt reduced to zero) is a meaningful offset but does not fully mitigate shrinking assets and equity instability. Technical signals are unavailable (neutral impact), while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Debt elimination
Eliminating debt reduces interest obligations and lender dependence, giving AdAlta greater financial flexibility while it develops its pipeline. However, the benefit is limited because the company still has weak cash generation and may require external funding.
Negative Factors
Revenue deterioration
The sustained decline to zero revenue indicates that AdAlta currently lacks a dependable commercial income stream. Without recurring product, licensing, or partnership revenue, funding for research and operations remains dependent on uncertain external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt elimination
Eliminating debt reduces interest obligations and lender dependence, giving AdAlta greater financial flexibility while it develops its pipeline. However, the benefit is limited because the company still has weak cash generation and may require external funding.
Read all positive factors
AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.64M
Dividend YieldN/A
Average Volume (3M)574.71K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue GrowthN/A
EPS Growth62.90%
CountryAU
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding3,212,169,000
10 Day Avg. Volume957,709
30 Day Avg. Volume574,705
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)16.60
Price to Sales (P/S)0.00
P/FCF Ratio-1.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AdAlta Ltd. Business Overview & Revenue Model
Company Description
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical t...
How the Company Makes Money
null...
AdAlta Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 301.92K | 0.00 | 677.01K | 1.74M | 3.47M | 2.75M |
| Gross Profit | 181.81K | 0.00 | 457.50K | 1.51M | 3.44M | 2.49M |
| EBITDA | -4.40M | -4.80M | -4.45M | -5.26M | -7.58M | -7.31M |
| Net Income | -4.36M | -4.68M | -4.50M | -5.38M | -4.85M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 1.85M | 1.72M | 2.14M | 5.57M | 7.73M | 10.65M |
| Cash, Cash Equivalents and Short-Term Investments | 1.58M | 1.28M | 1.31M | 3.13M | 4.79M | 8.66M |
| Total Debt | 0.00 | 0.00 | 1.77M | 2.70M | 4.01M | 4.00M |
| Total Liabilities | 2.07M | 1.35M | 2.74M | 3.54M | 5.82M | 5.27M |
| Stockholders Equity | -218.66K | 370.17K | -598.24K | 2.03M | 1.91M | 5.38M |
Cash Flow | ||||||
| Free Cash Flow | -2.44M | -4.44M | -2.94M | -5.32M | -5.13M | -4.11M |
| Operating Cash Flow | -2.44M | -4.44M | -2.94M | -5.26M | -5.13M | -4.09M |
| Investing Cash Flow | 109.61K | 0.00 | 109.61K | -62.40K | -2.13K | -25.23K |
| Financing Cash Flow | 2.29M | 4.42M | 999.06K | 3.67M | 1.27M | 7.02M |
AdAlta Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.53B | 130.07 | 6.03% | ― | -68.00% | -86.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$11.48M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
45 Neutral | AU$72.21M | -0.89 | -98.86% | ― | ― | -27.73% | |
44 Neutral | AU$9.64M | -1.74 | -6182.61% | ― | ― | 62.90% | |
38 Underperform | AU$110.08M | -7.05 | 84.67% | ― | ― | 42.51% |
* Healthcare Sector Average
AU:1AD
AdAlta Ltd.
―
―
―
AU:NEU
Neuren Pharmaceuticals Limited
20.57
0.59
2.95%
AU:IMM
Immutep Ltd
0.05
-0.20
-80.82%
AU:CMB
Regeneus Ltd.
0.45
-0.02
-5.26%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
-0.08
-18.18%
AdAlta Ltd. Corporate Events
AdAlta updates ASX corporate governance disclosures for 2026
Aug 21, 2026
AdAlta has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and has been approved by the board as at 20 August 2026. The company’s accompanying Append...
AdAlta Releases Annual Report for Year Ended 30 June 2026
Aug 21, 2026
AdAlta Limited has released its annual report for the year ended 30 June 2026, outlining its corporate directory, directors’ report, financial statements, and auditor’s report. The document provides a comprehensive overview of the comp...
AdAlta posts wider annual loss and flags going concern uncertainty
Aug 21, 2026
AdAlta Limited reported a net loss after tax of $4.68 million for the year ended 30 June 2026, a 4% increase on the prior year’s $4.50 million loss, and did not declare any dividends for the period. Net tangible assets per share improved to ...
AdAlta outlines global immunotherapy ambitions while flagging investment risks
Aug 13, 2026
AdAlta Limited has released an investor presentation outlining its strategy to commercialise life-saving cellular immunotherapies under an “East to West” approach, signalling ambitions to translate its research into marketed therapies ...
AdAlta’s EW-001 CAR-T Shows Promising Survival and Response in Advanced Mesothelioma
Aug 9, 2026
AdAlta reported that all five mesothelioma patients who remained on its Chinese investigator-initiated trial as of March 2026 were still alive and on study in July, extending evidence of sustained survival. Among 10 patients treated at higher EW-0...
AdAlta Posts Landmark Long-Term Responses in Mesothelioma CAR-T Trial
Aug 4, 2026
AdAlta has reported a major clinical milestone in its ongoing investigator-initiated trial of EW-001 in advanced mesothelioma, with the first patient to achieve complete tumour clearance remaining alive and cancer-free two years after a single dos...
AdAlta Advances EW-001 CAR-T Program and AI-Driven East-to-West Strategy
Jul 29, 2026
AdAlta has strengthened its position in solid tumour cell therapies by completing its initial US$1 million milestone investment in EW-001, securing rights to develop the CAR-T treatment outside Greater China and obtaining key clinical and manufact...
AdAlta Seeks ASX Quotation for Major New Share and Option Issue
Jul 1, 2026
AdAlta Limited has applied for quotation on the ASX of 37,500,000 new ordinary fully paid shares and 168,750,000 options expiring in June 2028. The issuance, lodged under an Appendix 2A, significantly increases the company’s quoted securitie...
AdAlta Seeks ASX Quotation for Nearly 265 Million New Securities
Jul 1, 2026
AdAlta Ltd. has applied to the ASX for quotation of 198,750,012 new ordinary fully paid shares and 66,250,001 options expiring in June 2028, all issued on 2 July 2026. The move significantly increases the company’s listed securities base, si...
AdAlta expands AI-driven drug development with Oktopi collaboration
Jul 1, 2026
AdAlta Limited has entered a strategic collaboration with Oktopi to deploy its AI-enabled, software-as-a-service knowledge platform across AdAlta’s medicine development programs, enhancing how the company plans research, identifies critical ...
AdAlta Issues 319.9 Million New Shares in Private Placement
Jun 25, 2026
AdAlta Limited has issued 319,937,238 new fully paid ordinary shares at $0.004 each to sophisticated investors under a private placement previously announced to the market. The company has lodged an application for quotation of these shares and co...
AdAlta seeks ASX quotation for major new share and option issue
Jun 25, 2026
AdAlta Ltd. has applied to the ASX for quotation of 319,937,238 ordinary fully paid shares under code 1AD and 142,083,332 options expiring 3 June 2028 under code 1ADO, with an issue date of 25 June 2026. The large volume of new shares and options ...
AdAlta targets sophisticated investors with speculative ASX-listed options offer
May 24, 2026
AdAlta Limited has issued a target market determination for a new series of quoted options, each allowing holders to acquire one fully paid ordinary share, to be offered under a prospectus dated 22 May 2026. The options, aimed at sophisticated and...
AdAlta files prospectus for options linked to A$2.5m placement to fund solid cancer immunotherapy push
May 24, 2026
AdAlta Limited, a Melbourne-based clinical-stage biotech, specialises in cellular immunotherapies for solid tumours and leverages an ‘East to West’ model that links Asian T cell therapy innovation with Western regulatory and commercial...
AdAlta hires cell therapy specialists to steer FDA path for mesothelioma CAR-T
May 24, 2026
AdAlta has engaged specialist consultancy Dark Horse Consulting Group to guide regulatory interactions with the US Food and Drug Administration for its lead CAR-T therapy, BZDS1901, as it prepares for an Australian Phase 1 clinical trial. The move...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.